β1-Integrin is highly expressed and is a negative prognostic factor for colon and pancreatic cancer patients and the gene plays a functional role in cell migration and invasion. In this study, we demonstrate that β1-integrin expression is regulated in pancreatic and colon cancer cells by the pro-oncogenic orphan nuclear receptor 4A1 (NR4A1, Nur77, TR3) and knockdown of this receptor by RNA interference decreases β1-integrin protein and mRNA expression, α5-integrin, and also expression of β1-integrin-dependent phosphorylation of FAK (pFak). Knockdown of NR4A1 also decreased migration and fibronectin-induced adhesion in pancreatic (Panc1, 2066 |
| INTRODUCTION
The nuclear receptor 4A (NR4A) subfamily of orphan receptors including NR4A1 (Nur77/TR3), NR4A2 (Nurr1), and NR4A3 (Nor1) are stress-inducible immediate early genes that play both unique and overlapping roles in metabolic, cardiovascular, neurological and immune functions, inflammation, and cancer. 1, 2 Although endogenous ligands for NR4A receptors have not been identified, there is evidence that ligands for these receptors acting as agonists or antagonists are emerging as a novel class of therapeutics. [2] [3] [4] [5] For example, Wu et al. 18 have characterized cytosporone and related synthetic analogs as NR4A1 ligands [6] [7] [8] [9] [10] and have shown that one of their analogs inhibits endotoxin-induced sepsis in RAW 264.7 cells and in vivo. 10 The mechanism of this NR4A1-dependent antiinflammatory response is due to ligand-induced dissociation of p38-NR4A1 interactions and restoration of the p65-NR4A1 complex resulting in inhibition of NFκB signaling. 10 In double knockout animals, the loss of both NR4A1 and NR4A3 results in the rapid development of acute myeloid leukemia in mice 11 indicating a tumor suppressor-like role for these receptors. In contrast, NR4A1 is overexpressed in many solid tumors and their derived cell lines, and in breast, colon, and lung tumors overexpression of NR4A1 is a negative prognostic factor. [12] [13] [14] [15] [16] [17] [18] Moreover, knockdown or overexpression of NR4A1
shows that this receptor is pro-oncogenic and regulates one or more of cell proliferation, survival and migration/invasion in lung,
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melanoma, lymphoma, kidney, pancreatic, colon, cervical, ovarian, and gastric cancer cells. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] 
| Chromatin immunoprecipitation
The chromatin immunoprecipitation (ChIP) assay was performed using Cells were analyzed by western blot as described previously.
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| Small interfering RNA interference assay
SiRNA experiments were conducted as described previously. [27] [28] [29] The siRNA complexes used in the study were as follows: siGL2-5′: CGU ACG CGG AAU ACU UCG A; siNR4A1: SASI_Hs02_00333289, 
| Statistical analysis
Statistical significance of differences between the treatment groups was determined as previously described.
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3 | RESULTS
| NR4A1 regulates β1-integrin gene expression
Knockdown of NR4A1 by RNAi in pancreatic (Panc1, L3.6 pL, and MiaPaCa2) ( expression of β1-integrin, phosphorylated FAK (pFAK), and α5-integrin in all three cell lines ( Fig. 2A) . Moreover, after knockdown of β1-integrin (siβ1-integrin), we also observed decreased expression of β1-integrin, α5-integrin, and pFAK (downstream from β1-integrin). Similar results were observed in RKO and SW480 cells; knockdown of NR4A1 decreased β1-integrin, α5-integrin and pFAK, and knockdown of β1-integrin also decreased pFAK and α5-integrin. (Figure 2B ) Treatment of the pancreatic cancer cell lines with 15 or 20 μM DIM-C-pPhCO 2 Me and DIM-C-pPhOH also decreased expression of β1-integrin, pFAK, and α5-integrin (Fig. 2C and D) and the NR4A1
antagonists caused similar effects in RKO and SW480 cells ( Fig. 2E and F) demonstrating that NR4A1 regulates β1-integrin in both pancreatic and colon cancer cells and that knockdown of NR4A1 (siNR4A1) or treatment with NR4A1 antagonist decreases β1-integrin expression. We also observed that DIM-C-pPhOH decreased β1-integrin and α5-integrin expression in tumor lysates from an orthotopic pancreatic cancer model using L3.6 pL cells ( Supplementary Fig. S1 ). Boyden chamber assay (Fig. 3A) and similar results were observed in RKO and SW480 colon cancer cells transfected with siNR4A1
( Fig. 3B) . Migration of Panc1, L3.6 pL, and MiaPaCa2 cells was also significantly decreased after treatment with the NR4A1 antagonists DIM-C-pPhOH and DIM-C-pPhCO 2 Me (Fig. 3C and D) and similar results were observed in RKO and SW480 cells treated with the same compounds ( Fig. 3E and F) .
We also investigated the antimigratory effects of DIM-C-pPhCO 2 Me in pancreatic cancer cells after knockdown of NR4A1 or β1-integrin. DIM-C-pPhCO 2 Me decreased migration; however, in cells depleted of NR4A1 or β1-integrin minimum inhibition was observed in cells after treatment with DIM-C-pPhCO 2 Me (Fig. 4A ) and similar results were observed in colon cancer cells (Fig. 4B ) and also with DIM-C-pPhOH ( Supplementary Fig. S2 ). These results not only confirm the importance of both NR4A1 and β1-integrin in cell migration but also demonstrate that in the absence of β1-integrin, DIM-C-pPhCO 2 Me-mediated antagonism of other NR4A1-mediated pro-oncogenic pathways has minimal effects on cell migration.
Moreover, in pancreatic and colon cancer cells transfected with siNR4A1, the resulting decreased migration was rescued by β1-integrin (ITGB1) gene overexpression (Fig. 4C) . Previous studies show that NR4A1-dependent anticancer activities of C-DIMs in colon and pancreatic cancer cells were due to modulation of nuclear NR4A1-mediated changes in gene expression 12, 14, 19, 26 and this contrasted to 
| Mechanism of NR4A1 regulation of β1-integrin
Previous studies in breast cancer cells showed that β1-integrin is regulated by a NR4A1/p300/Sp1 complex bound to a proximal GCrich region of the β1-integrin promoter (Fig. 6A ) 29 and this same complex also regulates survivin expression in pancreatic and colon cancer cells. 12, 26 The functional role of these complexes was investigated by RNAi, and knockdown of p300 decreased β1-integrin protein expression (Fig. 6B ) in the five pancreatic and colon cancer cell lines and this paralleled the effects observed after knockdown of NR4A1 or treatment with NR4A1 antagonists (Fig. 2) . In a separate (Fig. 6D) . This is the first example of an important role for NR4A1/Sp4-mediated transactivation, and examples of other genes regulated by this complex are currently being investigated.
| DISCUSSION
Integrins are heterodimeric cell surface receptors that consist of an α-and β-subunit and these receptors play critical roles in maintaining cellular homeostasis and also in several human pathologies. There are antagonists. 14, 19 Our recent study showed that these NR4A1 ligands also inhibit breast cancer cell migration through inhibition of β1-integrin expression which is an NR4A1-regulated gene in breast cancer cells. 29 There is also evidence that β1-integrin is a negative prognostic factor for colon and pancreatic patients and plays an important role in cancer cell migration/invasion and metastasis. [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] It was evident from the results of RNAi studies that decreased expression of NR4A1 resulted in decreased expression of β1-integrin RNA and protein, α5-integrin, and a β1-integrin-activated FAK gene phosphorylation (Figs. 1A,B and 2A,E) .
Moreover, siNR4A1 also decreased β1-integrin-regulated migration and adhesion (Figs. 3 and 5 ) and the effects of NR4A1 or β1-integrin knockdown were comparable indicating that NR4A1 regulates β1-integrin in pancreatic and colon cancer cells as previously observed for breast cancer cell lines. 29 We also observed that knockdown of NR4A1
by RNAi or treatment with DIM-C-pPhOH and DIM-C-pPhCO 2 Me gave comparable results demonstrating that these C-DIMs act as NR4A1
antagonists to decrease β1-integrin expression and thereby represent a novel class of agents targeting β1-integrin in pancreatic and colon cancer.
Although NR4A1 regulates expression of genes through binding as a monomer or dimer to cognate response elements in breast cancer cells, NR4A1 regulates expression of β1-integrin by cooperative interactions of NR4A1 and p300 with promoter DNA (GC-rich)-bound Sp1. 29 NR4A1/p300 also induced survivin expression through interactions with Sp1 bound to the GC-rich survivin promoter. 12 Results of RNAi and ChIP assays showed that in SW480 colon cancer cells, β1-integrin was regulated by an NR4A1/p300/Sp1 complex bound to the proximal GC-rich site of the β1-integrin promoter (Fig. 6A) . ChIP assays showed that Sp1, Sp3, and Sp4 bound the proximal GC-rich site in the β1-integrin promoter; however, it is clear from Sp knockdown studies that the functional Sp protein was cell context dependent ( Fig. 6C and D) .
Thus, Sp4 and to a lesser extent Sp3 in combination with NR4A1
and p300 also regulate β1-integrin expression is some colon and pancreatic cancer cell lines. The reason for the cell selective and functional role of Sp1, Sp3, and Sp4 in regulating β1-integrin expression via an NR4A1/p300/Sp complex is unclear and is currently being investigated.
In summary, results of this study demonstrate the role of NR4A1 in regulation of pancreatic and colon cancer cell migration through transcriptional activation of β1-integrin which is an NR4A1/p300/Sp-regulated gene. This observation is consistent with previous studies demonstrating that NR4A1 regulates multiple pro-oncogenic genes/pathways in solid tumors. We also show that C-DIM/NR4A1 antagonists represent a novel class of drugs that target β1-integrin in pancreatic and colon cancer, and current studies are focused on developing these compounds for future clinical applications.
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